Pathogenesis of alcoholic liver disease

Hepatology Research

Volumn 47, Issue 1, 2017, Pages 70-79

  Sugimoto, Kazushi ^a   Takei, Yoshiyuki ^a  

^a MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

adipokine; alcohol; cytochrome P450; epigenetic change; oxidative stress, intestinal bacterial flora

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; ALCOHOL DEHYDROGENASE; ALDEHYDE DEHYDROGENASE; CATALASE; CYTOCHROME P450 2E1; ENDOTOXIN; GLUTATHIONE; GLUTATHIONE PEROXIDASE; HORMONE SENSITIVE LIPASE; HYDROGEN PEROXIDE; HYDROXYL RADICAL; INSULIN RECEPTOR; INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 2; INTERLEUKIN 1BETA; INTERLEUKIN 6; LEPTIN; LIPOPOLYSACCHARIDE; MESSENGER RNA; NICOTINAMIDE ADENINE DINUCLEOTIDE; NITRIC OXIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; SUPEROXIDE DISMUTASE; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR;

ALCOHOL CONSUMPTION; ALCOHOL LIVER DISEASE; ALCOHOL METABOLISM; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISEASE COURSE; DNA METHYLATION; DYSBIOSIS; EPIGENETICS; GENE SILENCING; HUMAN; HYPOXEMIA; INSULIN RESISTANCE; INTESTINE FLORA; INTRAPERITONEAL FAT; LIPID METABOLISM; MOLECULAR DYNAMICS; NONHUMAN; OBESITY; OXIDATIVE STRESS; OXYGEN CONSUMPTION; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; RECEPTOR BINDING; REVIEW; SIGNAL TRANSDUCTION; STEATOSIS; TRANSCRIPTION REGULATION;

EID: 85008705424     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12736     Document Type: Review

References (103)

1. Rubin E, Lieber CS. Experimental alcoholic hepatitis: a new primate model. Science 1973; 182: 712–3.
2. Lieber CS, DeCarli LM. Ethanol oxidation by hepatic microsomes: adaptive increase after ethanol feeding. Science 1968; 162: 917–8.
3. 2 production by peroxisomes. Eur J Biochem 1988; 176: 477–84.
4. Iimuro Y, Bradford BU, Yamashina S et al. The glutathione precursor L-2-oxothiazolidine-4-carboxylic acid protects against liver injury due to chronic enteral ethanol exposure in the rat. Hepatology 2000; 31: 391–8.
5. Tsukamoto H, Lu SC. Current concepts in the pathogenesis of alcoholic liver injury. FASEB J 2001; 15: 1335–49.
6. Nakazawa H, Genka C, Fujishima M. Pathological aspects of active oxygens/free radicals. Jpn J Physiol 1996; 46: 15–32.
7. Reddy JK, Rao MS. Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation. Am J Physiol Gastrointest Liver Physiol 2006; 290: G852–8.
8. Bailey SM, Cunningham CC. Acute and chronic ethanol increases reactive oxygen species generation and decreases viability in fresh, isolated rat hepatocytes. Hepatology 1998; 28: 1318–26.
9. −/− mice fed alcohol. Free Radic Biol Med 2007; 42: 1470–80.
10. Koop DR, Morgan ET, Tarr GE, Coon MJ. Purification and characterization of a unique isozyme of cytochrome P-450 from liver microsomes of ethanol-treated rabbits. J Biol Chem 1982; 257: 8472–80.
11. Ekstrom G, Ingelman-Sundberg M. Rat liver microsomal NADPH-supported oxidase activity and lipid peroxidation dependent on ethanol-inducible cytochrome P-450 (P-450IIE1). Biochem Pharmacol 1989; 38: 1313–9.
12. Albano E, Clot P, Morimoto M, Tomasi A, Ingelman-Sundberg M, French SW. Role of cytochrome P4502E1-dependent formation of hydroxyethyl free radical in the development of liver damage in rats intragastrically fed with ethanol. Hepatology 1996; 23: 155–63.
13. Cederbaum AI, Wu D, Mari M, Bai J. CYP2E1-dependent toxicity and oxidative stress in HepG2 cells. Free Radic Biol Med 2001; 31: 1539–43.
14. Lu Y, Wu D, Wang X, Ward SC, Cederbaum AI. Chronic alcohol-induced liver injury and oxidant stress are decreased in cytochrome P4502E1 knockout mice and restored in humanized cytochrome P4502E1 knock-in mice. Free Radic Biol Med 2010; 49: 1406–16.
15. Anni H, Pristatsky P, Israel Y. Binding of acetaldehyde to a glutathione metabolite: mass spectrometric characterization of an acetaldehyde–cysteinylglycine conjugate. Alcohol Clin Exp Res 2003; 27: 1613–21.
16. Bailey SM, Patel VB, Young TA, Asayama K, Cunningham CC. Chronic ethanol consumption alters the glutathione/glutathione peroxidase-1 system and protein oxidation status in rat liver. Alcohol Clin Exp Res 2001; 25: 726–33.
17. Kehrer JP. The Haber–Weiss reaction and mechanisms of toxicity. Toxicology 2000; 149: 43–50.
18. Kohgo Y, Ohtake T, Ikuta K, Suzuki Y, Torimoto Y, Kato J. Dysregulation of systemic iron metabolism in alcoholic liver diseases. J Gastroenterol Hepatol 2008; 23(Suppl 1): S78–81.
19. Suzuki Y, Saito H, Suzuki M et al. Up-regulation of transferrin receptor expression in hepatocytes by habitual alcohol drinking is implicated in hepatic iron overload in alcoholic liver disease. Alcohol Clin Exp Res 2002; 26: 26S–31S.
20. Bridle K, Cheung TK, Murphy T et al. Hepcidin is down-regulated in alcoholic liver injury: implications for the pathogenesis of alcoholic liver disease. Alcohol Clin Exp Res 2006; 30: 106–12.
21. Videla L, Bernstein J, Israel Y. Metabolic alterations produced in the liver by chronic ethanol administration. Increased oxidative capacity. Biochem J 1973; 134: 507–14.
22. Tsukamoto H, Xi XP. Incomplete compensation of enhanced hepatic oxygen consumption in rats with alcoholic centrilobular liver necrosis. Hepatology 1989; 9: 302–6.
23. Oshita M, Sato N, Yoshihara H et al. Ethanol-induced vasoconstriction causes focal hepatocellular injury in the isolated perfused rat liver. Hepatology 1992; 16: 1007–13.
24. Oshita M, Takei Y, Kawano S et al. Roles of endothelin-1 and nitric oxide in the mechanism for ethanol-induced vasoconstriction in rat liver. J Clin Invest 1993; 91: 1337–42.
25. Nath B, Szabo G. Hypoxia and hypoxia inducible factors: diverse roles in liver diseases. Hepatology 2012; 55: 622–33.
26. Lehrke M, Lazar MA. Inflamed about obesity. Nat Med 2004; 10: 126–7.
27. Arita Y, Kihara S, Ouchi N et al. Paradoxical decrease of an adipose-specific protein, adiponectin in obesity. Biochem Biophys Res Commun 1999; 257: 79–83.
28. Shklyaev S, Aslanidi G, Tennant M et al. Sustained peripheral expression of transgene adiponectin offsets the development of diet-induced obesity in rats. Proc Natl Acad Sci USA 2003; 100: 14 217–22.
29. You M, Considine RV, Leone TC, Kelly DP, Crabb DW. Role of adiponectin in the protective action of dietary saturated fat against alcoholic fatty liver in mice. Hepatology 2005; 42: 568–77.
30. Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev 2005; 26: 439–51.
31. Xu A, Wang Y, Keshaw H, Xu LY, Lam KS, Cooper GJ. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 2003; 112: 91–100.
32. Chen X, Sebastian BM, Nagy LE. Chronic ethanol feeding to rats decreases adiponectin secretion by subcutaneous adipocytes. Am J Physiol Endocrinol Metab 2007; 292: E621–8.
33. Song Z, Zhou Z, Deaciuc I, Chen T, McClain CJ. Inhibition of adiponectin production by homocysteine: a potential mechanism for alcoholic liver disease. Hepatology 2008; 47: 867–79.
34. Ajmo JM, Liang X, Rogers CQ, Pennock B, You M. Resveratrol alleviates alcoholic fatty liver in mice. Am J Physiol Gastrointest Liver Physiol 2008; 295: G833–42.
35. Xu J, Lai KK, Verlinsky A et al. Synergistic steatohepatitis by moderate obesity and alcohol in mice despite increased adiponectin and p-AMPK. J Hepatol 2011; 55: 673–82.
36. Kasztelan-Szczerbinska B, Surdacka A, Slomka M et al. Association of serum adiponectin, leptin, and resistin concentrations with the severity of liver dysfunction and the disease complications in alcoholic liver disease. Mediators Inflamm 2013; 2013: 148526.
37. Andreelli F, Foretz M, Knauf C et al. Liver adenosine monophosphate-activated kinase-α2 catalytic subunit is a key target for the control of hepatic glucose production by adiponectin and leptin but not insulin. Endocrinology 2006; 147: 2432–41.
38. Caro JF, Kolaczynski JW, Nyce MR et al. Decreased cerebrospinal-fluid/serum leptin ratio in obesity: a possible mechanism for leptin resistance. Lancet 1996; 348: 159–61.
39. Brabant G, Muller G, Horn R, Anderwald C, Roden M, Nave H. Hepatic leptin signaling in obesity. FASEB J 2005; 19: 1048–50.
40. Honda H, Ikejima K, Hirose M et al. Leptin is required for fibrogenic responses induced by thioacetamide in the murine liver. Hepatology 2002; 36: 12–21.
41. Ikejima K, Takei Y, Honda H et al. Leptin receptor-mediated signaling regulates hepatic fibrogenesis and remodeling of extracellular matrix in the rat. Gastroenterology 2002; 122: 1399–410.
42. Imajo K, Fujita K, Yoneda M et al. Hyperresponsivity to low-dose endotoxin during progression to nonalcoholic steatohepatitis is regulated by leptin-mediated signaling. Cell Metab 2012; 16: 44–54.
43. Roth MJ, Baer DJ, Albert PS et al. Relationship between serum leptin levels and alcohol consumption in a controlled feeding and alcohol ingestion study. J Natl Cancer Inst 2003; 95: 1722–5.
44. Rachakonda V, Gabbert C, Raina A et al. Stratification of risk of death in severe acute alcoholic hepatitis using a panel of adipokines and cytokines. Alcohol Clin Exp Res 2014; 38: 2712–21.
45. Plomgaard P, Bouzakri K, Krogh-Madsen R, Mittendorfer B, Zierath JR, Pedersen BK. Tumor necrosis factor-α induces skeletal muscle insulin resistance in healthy human subjects via inhibition of Akt substrate 160 phosphorylation. Diabetes 2005; 54: 2939–45.
46. Lawler JF Jr, Yin M, Diehl AM, Roberts E, Chatterjee S. Tumor necrosis factor-α stimulates the maturation of sterol regulatory element binding protein-1 in human hepatocytes through the action of neutral sphingomyelinase. J Biol Chem 1998; 273: 5053–9.
47. Honchel R, Ray MB, Marsano L et al. Tumor necrosis factor in alcohol enhanced endotoxin liver injury. Alcohol Clin Exp Res 1992; 16: 665–9.
48. Kamimura S, Tsukamoto H. Cytokine gene expression by Kupffer cells in experimental alcoholic liver disease. Hepatology 1995; 22: 1304–9.
49. Enomoto N, Takei Y, Hirose M et al. Thalidomide prevents alcoholic liver injury in rats through suppression of Kupffer cell sensitization and TNF-α production. Gastroenterology 2002; 123: 291–300.
50. Iimuro Y, Gallucci RM, Luster MI, Kono H, Thurman RG. Antibodies to tumor necrosis factor α attenuate hepatic necrosis and inflammation caused by chronic exposure to ethanol in the rat. Hepatology 1997; 26: 1530–7.
51. Felver ME, Mezey E, McGuire M et al. Plasma tumor necrosis factor α predicts decreased long-term survival in severe alcoholic hepatitis. Alcohol Clin Exp Res 1990; 14: 255–9.
52. McClain CJ, Barve S, Deaciuc I, Kugelmas M, Hill D. Cytokines in alcoholic liver disease. Semin Liver Dis 1999; 19: 205–19.
53. Park EJ, Lee JH, Yu GY et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 2010; 140: 197–208.
54. Rotter V, Nagaev I, Smith U. Interleukin-6 (IL-6) induces insulin resistance in 3 T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-α, overexpressed in human fat cells from insulin-resistant subjects. J Biol Chem 2003; 278: 45777–84.
55. Simons PJ, van den Pangaart PS, Aerts JM, Boon L. Pro-inflammatory delipidizing cytokines reduce adiponectin secretion from human adipocytes without affecting adiponectin oligomerization. J Endocrinol 2007; 192: 289–99.
56. Hill DB, Marsano L, Cohen D, Allen J, Shedlofsky S, McClain CJ. Increased plasma interleukin-6 concentrations in alcoholic hepatitis. J Lab Clin Med 1992; 119: 547–52.
57. Cressman DE, Greenbaum LE, DeAngelis RA et al. Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice. Science 1996; 274: 1379–83.
58. Gao B. Cytokines, STATs and liver disease. Cell Mol Immunol 2005; 2: 92–100.
59. El-Assal O, Hong F, Kim WH, Radaeva S, Gao B. IL-6-deficient mice are susceptible to ethanol-induced hepatic steatosis: IL-6 protects against ethanol-induced oxidative stress and mitochondrial permeability transition in the liver. Cell Mol Immunol 2004; 1: 205–11.
60. Kwon HJ, Won YS, Park O et al. Aldehyde dehydrogenase 2 deficiency ameliorates alcoholic fatty liver but worsens liver inflammation and fibrosis in mice. Hepatology 2014; 60: 146–57.
61. Bigatello LM, Broitman SA, Fattori L et al. Endotoxemia, encephalopathy, and mortality in cirrhotic patients. Am J Gastroenterol 1987; 82: 11–5.
62. Nanji AA, Khettry U, Sadrzadeh SM, Yamanaka T. Severity of liver injury in experimental alcoholic liver disease. Correlation with plasma endotoxin, prostaglandin E2, leukotriene B4, and thromboxane B2. Am J Pathol 1993; 142: 367–73.
63. Fujimoto M, Uemura M, Nakatani Y et al. Plasma endotoxin and serum cytokine levels in patients with alcoholic hepatitis: relation to severity of liver disturbance. Alcohol Clin Exp Res 2000; 24: 48S–54S.
64. Bode C, Bode JC. Effect of alcohol consumption on the gut. Best Pract Res Clin Gastroenterol 2003; 17: 575–92.
65. Rao RK, Seth A, Sheth P. Recent advances in alcoholic liver disease. I. Role of intestinal permeability and endotoxemia in alcoholic liver disease. Am J Physiol Gastrointest Liver Physiol 2004; 286: G881–4.
66. Atkinson KJ, Rao RK. Role of protein tyrosine phosphorylation in acetaldehyde-induced disruption of epithelial tight junctions. Am J Physiol Gastrointest Liver Physiol 2001; 280: G1280–8.
67. Wang Y, Tong J, Chang B, Wang B, Zhang D, Wang B. Effects of alcohol on intestinal epithelial barrier permeability and expression of tight junction-associated proteins. Mol Med Rep 2014; 9: 2352–6.
68. Sheth P, Seth A, Atkinson KJ et al. Acetaldehyde dissociates the PTP1B-E-cadherin-β-catenin complex in Caco-2 cell monolayers by a phosphorylation-dependent mechanism. Biochem J 2007; 402: 291–300.
69. Salaspuro M. Bacteriocolonic pathway for ethanol oxidation: characteristics and implications. Ann Med 1996; 28: 195–200.
70. Bull-Otterson L, Feng W, Kirpich I et al. Metagenomic analyses of alcohol induced pathogenic alterations in the intestinal microbiome and the effect of Lactobacillus rhamnosus GG treatment. PLoS One 2013; 8: e53028.
71. Canesso MCC, Lacerda NL, Ferreira CM et al. Comparing the effects of acute alcohol consumption in germ-free and conventional mice: the role of the gut microbiota. BMC Microbiol 2014; 14: 240.
72. Bode C, Kolepke R, Schafer K, Bode JC. Breath hydrogen excretion in patients with alcoholic liver disease – evidence of small intestinal bacterial overgrowth. Z Gastroenterol 1993; 31: 3–7.
73. Hauge T, Persson J, Danielsson D. Mucosal bacterial growth in the upper gastrointestinal tract in alcoholics (heavy drinkers). Digestion 1997; 58: 591–5.
74. Gabbard SL, Lacy BE, Levine GM, Crowell MD. The impact of alcohol consumption and cholecystectomy on small intestinal bacterial overgrowth. Dig Dis Sci 2014; 59: 638–44.
75. Bhonchal S, Nain CK, Taneja N et al. Modification of small bowel microflora in chronic alcoholics with alcoholic liver disease. Trop Gastroenterol 2007; 28: 64–6.
76. Chen Y, Yang F, Lu H et al. Characterization of fecal microbial communities in patients with liver cirrhosis. Hepatology 2011; 54: 562–72.
77. Mutlu EA, Gillevet PM, Rangwala H et al. Colonic microbiome is altered in alcoholism. Am J Physiol Gastrointest Liver Physiol 2012; 302: G966–78.
78. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005; 115: 1343–51.
79. Hellerstedt WL, Jeffery RW, Murray DM. The association between alcohol intake and adiposity in the general population. Am J Epidemiol 1990; 132: 594–611.
80. Jequier E. Alcohol Intake and body weight: a paradox. Am J Clin Nutr 1999; 69: 173–4.
81. Renaud S, de Lorgeril M. Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet. 1992; 339: 1523–6.
82. Stein JH, Keevil JG, Wiebe DA, Aeschlimann S, Folts JD. Purple grape juice improves endothelial function and reduces the susceptibility of LDL cholesterol to oxidation in patients with coronary artery disease. Circulation 1999; 100: 1050–5.
83. Flanagan DE, Moore VM, Godsland IF, Cockington RA, Robinson JS, Phillips DI. Alcohol consumption and insulin resistance in young adults. Eur J Clin Invest 2000; 30: 297–301.
84. Mukamal KJ, Conigrave KM, Mittleman MA et al. Roles of drinking pattern and type of alcohol consumed in coronary heart disease in men. N Engl J Med 2003; 348: 109–18.
85. Koppes LL, Dekker JM, Hendriks HF, Bouter LM, Heine RJ. Moderate alcohol consumption lowers the risk of type 2 diabetes: a meta-analysis of prospective observational studies. Diabetes Care 2005; 28: 719–25.
86. Hong J, Smith RR, Harvey AE, Nunez NP. Alcohol consumption promotes insulin sensitivity without affecting body fat levels. Int J Obes (Lond) 2009; 33: 197–203.
87. Alkerwi A, Boutsen M, Vaillant M et al. Alcohol consumption and the prevalence of metabolic syndrome: a meta-analysis of observational studies. Atherosclerosis 2009; 204: 624–35.
88. Zein NN, Abdulkarim AS, Wiesner RH, Egan KS, Persing DH. Prevalence of diabetes mellitus in patients with end-stage liver cirrhosis due to hepatitis C, alcohol, or cholestatic disease. J Hepatol 2000; 32: 209–17.
89. Raynard B, Balian A, Fallik D et al. Risk factors of fibrosis in alcohol-induced liver disease. Hepatology 2002; 35: 635–8.
90. de la Monte SM, Yeon JE, Tong M et al. Insulin resistance in experimental alcohol-induced liver disease. J Gastroenterol Hepatol 2008; 23: e477–86.
91. Pang M, de la Monte SM, Longato L et al. PPARδ agonist attenuates alcohol-induced hepatic insulin resistance and improves liver injury and repair. J Hepatol 2009; 50: 1192–201.
92. Tuma DJ, Casey CA, Sorrell MF. Chronic ethanol-induced impairments in receptor-mediated endocytosis of insulin in rat hepatocytes. Alcohol Clin Exp Res 1991; 15: 808–13.
93. Patel BC, D'Arville C, Iwahashi M, Simon FR. Impairment of hepatic insulin receptors during chronic ethanol administration. Am J Physiol 1991; 261: G199–205.
94. Ramirez T, Longato L, Dostalek M, Tong M, Wands JR, de la Monte SM. Insulin resistance, ceramide accumulation and endoplasmic reticulum stress in experimental chronic alcohol-induced steatohepatitis. Alcohol Alcohol 2013; 48: 39–52.
95. Schattenberg JM, Wang Y, Singh R, Rigoli RM, Czaja MJ. Hepatocyte CYP2E1 overexpression and steatohepatitis lead to impaired hepatic insulin signaling. J Biol Chem 2005; 280: 9887–94.
96. Onishi Y, Honda M, Ogihara T et al. Ethanol feeding induces insulin resistance with enhanced PI 3-kinase activation. Biochem Biophys Res Commun 2003; 303: 788–94.
97. Lu SC, Huang ZZ, Yang H, Mato JM, Avila MA, Tsukamoto H. Changes in methionine adenosyltransferase and S-adenosylmethionine homeostasis in alcoholic rat liver. Am J Physiol Gastrointest Liver Physiol 2000; 279: G178–85.
98. Philibert RA, Plume JM, Gibbons FX, Brody GH, Beach SR. The impact of recent alcohol use on genome wide DNA methylation signatures. Front Genet 2012; 3: 54.
99. Zhang R, Miao Q, Wang C et al. Genome-wide DNA methylation analysis in alcohol dependence. Addict Biol 2013; 18: 392–403.
100. Shepard BD, Tuma PL. Alcohol-induced protein hyperacetylation: mechanisms and consequences. World J Gastroenterol 2009; 15: 1219–30.
101. You M, Jogasuria A, Taylor C, Wu J. Sirtuin 1 signaling and alcoholic fatty liver disease. Hepatobiliary Surg Nutr 2015; 4: 88–100.
102. Day CP, James OF. Steatohepatitis: a tale of two “hits”? Gastroenterology 1998; 114: 842–5.
103. Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 2010; 52: 1836–46.